Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

TLDR

Ductal adenocarcinoma dominates pancreatic cancers, and high‑quality multiphase imaging distinguishes resectable from unresectable disease while systemic therapy is employed across neoadjuvant, adjuvant, and advanced settings. Clinical trials are essential for advancing pancreatic cancer treatment. The NCCN Guidelines for Pancreatic Adenocarcinoma outline diagnosis and treatment strategies involving systemic therapy, radiation, and surgery.

Abstract

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.